Nexstim - Research and Development

Nexstim offers targeted and effective therapies and diagnostics for challenging brain diseases and disorders. Our technology is solidly grounded in scientific and clinical research. We closely collaborate with key opinion leaders who, like us, believe noninvasive brain stimulation harnesses the brain's own healing power—neuroplasticity. Nexstim is helping patients—and their families—get back the life they feared they had lost.

All

Financial

Customers and Trade

Research and Development

Management

08-20-2021

Nexstim Reaches 208 Completed Treatment Sessions – Continues to Report a Remission Rate Greater than 50% of MDD Patients in the Patient Registry

07-01-2021

Nexstim Plc provides an update on the pilot study in chronic pain treatment at Helsinki University Hospital

06-21-2021

Nexstim Continues to Report Very Promising MDD Treatment Outcomes with Remission Rate Greater than 50%

05-17-2021

Impressive New Study Results Suggest Potential New Therapeutic Use for Nexstim SmartFocus® nTMS in Postsurgical Rehabilitation of Paresis

03-12-2021

Nexstim Gives an Update on its Promising Treatment Results of Major Depressive Disorder

03-03-2021

Nexstim Plc provides encouraging results of the initial pilot study in severe depression at Kuopio University Hospital

01-13-2021

New Study Presents Impressive Results of Nexstim SmartFocus® nTMS Language Mapping

11-30-2020

Nexstim Secures Business Finland Funding for the Development of Accelerated iTBS Protocols

11-27-2020

Nexstim Plc provides an update on the pilot study in severe depression at Kuopio University Hospital

11-18-2020

Nexstim Plc signs a purchase agreement worth EUR 0.9 million to develop and deliver two prototype systems for a research project

10-14-2020

Nexstim Podium Webinars Demonstrate How Nexstim Systems Have Advanced the Standard of Care for Patients

10-05-2020

News